US Stocks
US Options
Emerging Asia
GBP Cash Savings
Charts & Tools
Paper Trading
Extended Hours
Wall Street Journal
TradingViewK
KNSA
Kiniksa Pharmaceuticals Internat…
41.67
0.68+1.66%After Hours: 41.67 0.00 0.00%16:10 12/05 EST
OPEN/PREV CLOSE41.12/40.99
TODAY RANGE40.31-42.00
VOL339.54K
MARKET CAP3.16B
52 WEEK RANGE17.82-42.98
AVG VOL (3M)429.35K
% TURNOVER0.45%
TURNOVER--
P/E (TTM)92.95
% RANGE4.07%
EPS(TTM)0.4483
P/E(FORWARD)46.30
P/B5.87
BVPS7.10
DIVIDEND--
P/S7.14
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.82B
SHARES OUTSTANDING75.80M
NEXT EARNINGS02/16-02/27
FREE FLOAT43.64M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·11/23 22:16
How Investors Are Reacting To Kiniksa Pharmaceuticals (KNSA) Raised Outlook Following Strong Arcalyst Sales
Simply Wall St·11/20 15:21
A Look at Kiniksa Pharmaceuticals (KNSA) Valuation Following Raised Guidance on Strong Q3 Earnings
TipRanks·11/18 14:26
Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies
Simply Wall St·11/14 11:08
Exploring High Growth Tech Stocks in the US Market
Simply Wall St·11/09 01:29
Is Kiniksa’s Upbeat 2025 Sales Outlook Reshaping the Investment Case for KNSA?
Simply Wall St·11/04 16:24
Kiniksa Pharmaceuticals (KNSA): Valuation Insights Following Upgraded 2025 Sales Guidance and Profitability Shift
Simply Wall St·10/31 09:35
The Bull Case For Kiniksa Pharmaceuticals (KNSA) Could Change Following ARCALYST Sales Surge and Return to Profitability
Reuters·10/30 20:47
Kiniksa CFO Mark Ragosa Reports Sale of Common Shares
Seeking Alpha·10/30 13:05
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
NASDAQ·10/30 12:25
New Strong Sell Stocks for Oct. 30th
Simply Wall St·10/30 01:34
Kiniksa Pharmaceuticals (KNSA) Profit Surge Challenges Valuation Caution as Growth Outpaces Peers
Dow Jones·10/29 18:19
Kiniksa Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Same Industry
Name/Symbol
Change%
Price